rs2230926 — TNFAIP3 F127C

Missense variant in the A20 ubiquitin-editing enzyme that weakens NF-kB negative feedback, increasing susceptibility to autoimmune and inflammatory diseases

See your personal result for TNFAIP3

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

TNFAIP3 F127C — When the Immune Brake Slips

Your immune system maintains a delicate balance between fighting threats and attacking your own body. At the center of this balance sits A20, a protein encoded by the TNFAIP3 gene11 A20, a protein encoded by the TNFAIP3 gene
TNFAIP3 stands for TNF Alpha Induced Protein 3; A20 is its common protein name that functions as a master brake on inflammation. The F127C variant (rs2230926) weakens this brake, and the consequences ripple through your immune system — from joints to gut lining to salivary glands.

The Mechanism

A20 is a ubiquitin-editing enzyme22 ubiquitin-editing enzyme
Ubiquitin is a small protein tag that cells attach to other proteins to control their fate — marking them for destruction, altering their activity, or changing their interactions with a remarkable dual function. Its N-terminal OTU domain strips K63-linked ubiquitin chains33 N-terminal OTU domain strips K63-linked ubiquitin chains
K63 ubiquitin chains activate inflammatory signaling proteins; removing them shuts the signal down from signaling proteins like RIP1, while its C-terminal zinc finger domain adds K48-linked chains44 C-terminal zinc finger domain adds K48-linked chains
K48 ubiquitin chains tag proteins for destruction by the proteasome that target them for proteasomal degradation. This two-step process — deactivate then destroy — efficiently terminates NF-kB signaling after it has served its purpose.

When TNF-alpha or bacterial products trigger inflammation, NF-kB activates and rapidly induces A20 expression as a negative feedback loop55 rapidly induces A20 expression as a negative feedback loop
A20's own promoter contains NF-kB binding sites, so inflammation triggers its own off-switch. The F127C variant sits in the OTU deubiquitinase domain, and the cysteine substitution reduces A20's ability to inhibit TNF-induced NF-kB activation66 cysteine substitution reduces A20's ability to inhibit TNF-induced NF-kB activation
Functional studies show the Cys127 variant is less effective at suppressing NF-kB than the normal Phe127 form. The result: inflammatory signals persist longer and reach higher intensity than they should.

Beyond immune signaling, A20 plays a direct role in gut barrier integrity. TNFAIP3 maintains intestinal epithelial tight junctions77 TNFAIP3 maintains intestinal epithelial tight junctions
A20 deubiquitinates occludin, a key tight junction protein, preventing its degradation and maintaining barrier function by regulating the ubiquitination of occludin. Mice lacking TNFAIP3 show increased intestinal permeability, while overexpression protects against barrier breakdown — directly linking A20 function to gut health.

The Evidence

The F127C variant has been associated with a striking breadth of autoimmune conditions. A genome-wide association study of 1,239 SLE cases88 genome-wide association study of 1,239 SLE cases
Study included 1,629 controls of European ancestry found rs2230926 independently associated with systemic lupus erythematosus (OR 2.0, 95% CI 1.4-3.0). Meta-analysis of 18,501 SLE patients and 30,435 controls99 Meta-analysis of 18,501 SLE patients and 30,435 controls
Analysis across 23 studies from 20 publications confirmed the association in both Europeans (OR 2.25, P<10-9) and Asians (OR 1.9, P=8.6x10-11). In the Japanese population specifically, the odds ratio was 1.92 (95% CI 1.53-2.41)1010 odds ratio was 1.92 (95% CI 1.53-2.41).

For rheumatoid arthritis, a meta-analysis of 21 case-control studies1111 meta-analysis of 21 case-control studies
Included stratification by ethnicity showing significant effects in Asian populations found rs2230926 increases risk with OR 1.39 (95% CI 1.11-1.72). A separate sequencing study across multiple autoimmune diseases1212 sequencing study across multiple autoimmune diseases
Genotyped rs2230926 in 1,513 controls and patients with nine different autoimmune conditions demonstrated significant associations with Sjogren's syndrome (OR 3.38, P=0.038), Crohn's disease (OR 2.25, P=0.041), psoriasis (OR 2.17, P=0.037), and rheumatoid arthritis (OR 1.9, P=0.025).

The Sjogren's syndrome association is particularly notable. In a Greek cohort of 327 primary Sjogren's patients1313 In a Greek cohort of 327 primary Sjogren's patients
Compared against 448 healthy controls, the variant frequency was 8.0% versus 3.6% in controls (OR 2.3). Among patients who developed lymphoma before age 40, the frequency reached 18.2% (OR 6.0, 95% CI 1.8-19.8). Carriers showed elevated Bcl-XL expression — evidence of abnormal NF-kB activation providing a survival signal to B cells that can drive lymphoma.

The variant shows dramatic population stratification: the G allele frequency is approximately 3.3% in Europeans, 5.8% in East Asians, 3.1% in South Asians, and 36.7% in African populations. This high frequency in African populations suggests possible balancing selection, where the variant may confer advantages against certain infections despite increasing autoimmune risk.

Practical Implications

If you carry the G allele, your NF-kB inflammatory pathway has a weakened brake. This means your immune system is predisposed to sustained inflammatory responses that can target your own tissues. The practical value of knowing this genotype lies in targeted monitoring, NF-kB-modulating interventions, and awareness of which autoimmune symptoms to take seriously.

Curcumin (the active compound in turmeric) is one of the most studied natural NF-kB inhibitors. Clinical evidence supports its anti-inflammatory effects1414 Clinical evidence supports its anti-inflammatory effects
A capsule combining 150 mg curcumin, 75 mg resveratrol, and 150 mg EGCG reduced TNF-alpha-induced NF-kB activation in healthy volunteers at doses of 500-1,000 mg daily (as bioavailable formulations). Omega-3 fatty acids deserve special attention: the VITAL trial of 25,871 participants1515 VITAL trial of 25,871 participants
Randomized, double-blind, placebo-controlled trial over 5.3 years found that vitamin D supplementation reduced autoimmune disease incidence by 22% and omega-3s by 15%, with omega-3 benefits persisting two years after supplementation ended.

Vitamin D optimization is particularly relevant because vitamin D directly modulates NF-kB signaling and T-cell differentiation. For carriers of this variant, maintaining serum 25(OH)D above 40 ng/mL may provide additional immune-regulatory benefit beyond what standard recommendations offer.

Interactions

The TNFAIP3 F127C variant interacts with the broader autoimmune risk landscape. Carriers who also have PTPN22 R620W (rs2476601) face compounded autoimmune susceptibility, as both variants independently impair immune tolerance through different mechanisms — PTPN22 by lowering T-cell activation thresholds, and TNFAIP3 by prolonging NF-kB inflammatory signaling. The combination may be particularly relevant for rheumatoid arthritis and SLE risk.

TLR4 variants (rs4986790) may modulate the effects of impaired A20 function. Since A20 normally terminates NF-kB signaling downstream of TLR4, individuals with both altered TLR4 sensitivity and weakened A20 braking could have amplified or dampened inflammatory responses depending on which TLR4 variant they carry.

NOD2 variants (rs2066844, rs2066845) act in the same bacterial-sensing and NF-kB activation pathway in the gut. A20 normally dampens NF-kB signals triggered by NOD2 activation, so carriers of both NOD2 gain-of-function variants and TNFAIP3 loss-of-function variants may face compounded Crohn's disease risk through excessive intestinal NF-kB activity.

Genotype Interpretations

What each possible genotype means for this variant.

TT Normal NF-kB Regulation Normal

Standard A20 function with effective NF-kB negative feedback regulation

You have two copies of the common T allele (encoding phenylalanine at position 127), which produces fully functional A20 protein. Your NF-kB inflammatory pathway has an intact negative feedback brake, and your A20-mediated regulation of intestinal tight junctions is normal. About 93.5% of people of European descent share this genotype. Your baseline risk for autoimmune conditions is at population average from this variant — autoimmune disease can still occur through other genetic and environmental factors, but TNFAIP3 F127C is not contributing.

GT Reduced NF-kB Regulation Intermediate

One copy of the F127C variant moderately impairs A20's ability to brake NF-kB inflammatory signaling

The heterozygous state produces both normal (Phe127) and variant (Cys127) A20 protein. Since A20 functions as a homodimer in some contexts, even partial replacement with the less effective variant can reduce overall NF-kB inhibition. Studies in Sjogren's syndrome patients show that heterozygous carriers have elevated Bcl-XL mRNA transcripts compared to non-carriers (2.7 vs 1.6, P=0.03), indicating measurable NF-kB pathway activation even with one copy.

The autoimmune associations are broad: SLE (OR ~2.0 in European populations), Sjogren's syndrome (OR 2.3), Crohn's disease (OR 2.25), psoriasis (OR 2.17), and rheumatoid arthritis (OR 1.4-1.9). The risk is particularly elevated for lupus nephritis and hematologic manifestations of SLE. Your gut barrier function may be modestly affected due to A20's role in maintaining tight junction integrity through occludin regulation.

GG Impaired NF-kB Regulation High Risk

Two copies of F127C substantially impair A20 function, creating a significantly weakened NF-kB brake

With both copies encoding the Cys127 variant, all A20 protein in your cells has reduced deubiquitinase activity against K63-linked ubiquitin chains on NF-kB signaling intermediates like RIP1. This means every inflammatory trigger — from bacterial products in the gut to TNF-alpha from immune cells — generates more prolonged and intense NF-kB activation than normal. The persistent NF-kB activity drives excess production of inflammatory cytokines (TNF-alpha, IL-6, IL-1beta) and provides survival signals to autoreactive B cells through Bcl-XL upregulation.

The gut barrier implications are particularly important for homozygotes. A20 normally deubiquitinates occludin at tight junctions, preventing its degradation. With impaired A20 function, intestinal permeability may increase, allowing bacterial products to cross the gut barrier and further fuel systemic NF-kB activation — creating a vicious cycle of gut leakiness and systemic inflammation.

In the Sjogren's syndrome-lymphoma cohort, the strongest effects were seen in carriers with early disease onset, where the OR reached 6.0 for developing B-cell lymphoma. This reflects the cumulative effect of sustained NF-kB-driven B-cell survival signaling over time.